These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32031601)

  • 1. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?
    Dykun I; Mahabadi AA; Rassaf T
    Eur Heart J; 2020 Jun; 41(24):2331. PubMed ID: 32031601
    [No Abstract]   [Full Text] [Related]  

  • 2. Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?
    Gragnano F; Calabrò P
    Eur Heart J; 2020 Jun; 41(24):2332. PubMed ID: 32031600
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
    ; ; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):348-353. PubMed ID: 32205101
    [No Abstract]   [Full Text] [Related]  

  • 4. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
    Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F; Baigent C; Catapano AL; Koskinas KC; Casula M; Badimon L; Chapman MJ; De Backer GG; Delgado V; Ference BA; Graham IM; Halliday A; Landmesser U; Mihaylova B; Pedersen TR; Riccardi G; Richter DJ; Sabatine MS; Taskinen MR; Tokgozoglu L; Wiklund O;
    Eur Heart J; 2020 Jan; 41(1):111-188. PubMed ID: 31504418
    [No Abstract]   [Full Text] [Related]  

  • 6. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 7. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 8. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Kardiol Pol; 2016; 74(11):1234-1318. PubMed ID: 27910077
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future.
    Catapano AL; Ray KK; Tokgözoglu L
    Atherosclerosis; 2022 Jan; 340():51-52. PubMed ID: 34863532
    [No Abstract]   [Full Text] [Related]  

  • 10. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 11. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 12. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.
    Rallidis LS
    Atherosclerosis; 2020 Jan; 292():231-233. PubMed ID: 31784033
    [No Abstract]   [Full Text] [Related]  

  • 13. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 14. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

  • 15. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 16. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman M; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D; ;
    Atherosclerosis; 2011 Jul; 217(1):3-46. PubMed ID: 21882396
    [No Abstract]   [Full Text] [Related]  

  • 17. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
    ; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540
    [No Abstract]   [Full Text] [Related]  

  • 19. 'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias.
    Eur Heart J; 2016 Oct; 37(39):2966. PubMed ID: 27923853
    [No Abstract]   [Full Text] [Related]  

  • 20. Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.
    Lüscher TF
    Eur Heart J; 2016 Oct; 37(39):2963-2965. PubMed ID: 27923852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.